Mega roles of microRNAs in regulation of skeletal muscle health and disease

Mridula Sharma1*, Prasanna Kumar Juvvuna1, Himani Kukreti1 and Craig McFarlane2

1 Department of Biochemistry, YLL School of Medicine, National University of Singapore, Singapore, Singapore
2 Brenner Centre for Molecular Medicine, Singapore Institute for Clinical Sciences (A*STAR), Singapore, Singapore

Skeletal muscle is a dynamic tissue with remarkable plasticity. Skeletal muscle growth and regeneration are highly organized processes thus it is not surprising that a high degree of complexity exists in the regulation of these processes. Recent discovery of non-coding microRNAs (miRNAs) has prompted extensive research in understanding the roles of these molecules in skeletal muscle. Research so far shows that miRNAs play a very significant role at every aspect of muscle biology. Besides muscle growth, development, and regeneration miRNAs are also involved in the pathology of muscle diseases and metabolism. In this review, recent advancements in miRNA function during myogenesis, exercise, atrophy, aging, and dystrophy are discussed.

Keywords: miRNAs, exercise, atrophy signaling, aging, myogenesis

MiRNA BIOGENESIS

MiRNAs are short non-coding RNAs (~22 nucleotides), involved in the regulation of gene expression post-transcriptionally. Ever since the discovery of Lin-4 miRNA in C. elegans, by Lee et al. (1993), thousands of miRNAs and their targets have been identified. The advancements made in miRNA research prove that miRNAs are crucial for development, physiology and metabolism (Bushati and Cohen, 2007; Fineberg et al., 2009; Leung and Sharp, 2010). Distinct miRNAs potentially target an extensive set of mRNAs depending on their seed sequence and the target mRNA 3′ UTR sequence (Ambros, 2004; Bushati and Cohen, 2007; Bartel, 2009). MiRNAs are transcribed by Pol II or Pol III as individual miRNAs (monocistronic) or in clusters (polycistronic) from non-coding RNA genes (intergenic) or within the protein coding genes (intragenic). Most miRNAs are transcribed by RNA polymerase II as long primary miRNA (pre-miRNA) transcripts, which are then processed into ~70 nt (pre-miRNA) hairpin like RNA duplex by Drosha (Denli et al., 2004; Han et al., 2004, 2006). Pre-miRNAs are processed by Dicer in association with other RNA-binding proteins in cytoplasm giving rise to mature miRNA (Chendrimada et al., 2005; Lee et al., 2006). MiRNAs contribute to post-transcriptional regulation of gene expression by gene silencing. The seed sequence (2 to 8 nucleotides on the 5′ end of miRNA sequence) of miRNA base-pair to the target mRNAs within the 3′ UTR or sometimes other mRNA regions in association with Argonaute proteins and normally lead to miRNA translational repression or destabilization and degradation (Meister and Tuschl, 2004; Du and Zamore, 2005; Zhao and Srivastava, 2007). Conserved seed sequence of miRNA enables targeting multiple mRNA targets; on the other hand a single mRNA can be targeted by more than one miRNA (Doench and Sharp, 2004; Brennecke et al., 2005; Lewis et al., 2005; Grimson et al., 2007; Bartel, 2009; Brodersen and Voinnet, 2009).

Several miRNAs are ubiquitously expressed whereas some are tissue specific and some are enriched in specific tissues. MiRNAs miR-1, miR-133a, miR-133b, miR-206, miR-208, miR-208b, miR-486, and miR-499 are Muscle enriched miRNAs so called myomiRs (McCarthy and Esser, 2007; Callis et al., 2008). Muscle regulatory factors (MRFs) like Myf5, Myogenin, MyoD, and Mrf4 play a very significant role in myogenesis. MRFs are involved in regulation of myomiR expression (Zhao et al., 2005; Rao et al., 2006). These myomiRs are differentially regulated during myogenesis, development, degeneration, atrophy, various myopathies, and exercise. In addition to the myomiRs, other miRNAs are implicated in myogenesis and muscle pathology (Table 1); hence in this review functions of both myomiRs and other miRNAs in skeletal muscle are discussed.

MiRNAs IN MYOGENESIS

A cluster of myomiRs including miR-1, miR-133, and miR-206 plays a role in myogenesis, and muscle regeneration (Rao et al., 2006). Myogenesis involves proliferation and differentiation of myoblasts during pre- and postnatal stages. MiR-1 represses histone deacetylase 4 (HDAC4), which is a transcriptional repressor of MEF2- activated muscle gene expression, hence promotes myoblast differentiation whereas miR-133 enhances myoblast proliferation by targeting serum response factor (SRF), a transcription factor involved in muscle differentiation (Miano, 2003; Jian-Fu et al., 2005). On the other hand, miR-206 promotes differentiation of myoblasts in-vitro by down-regulation of Pola 1, a subunit of DNA polymerase α (Kim et al., 2006). DNA polymerase α is necessary for cell proliferation and thus inhibition of Pola 1 by miR-206 resulted in inhibition of myoblast proliferation.
Table 1 | Overview of miRNAs differentially regulated in myogenesis, exercise, atrophy, aging, and Duchenne muscular dystrophy and their functional roles in regulation, maintenance, and pathology of skeletal muscle.

| Condition                        | MicroRNA        | Function                                                                                                                                 |
|----------------------------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------|
| Myogenesis                       | miR-1           | Promotes myoblast differentiation and regeneration by down regulating HDAC4 that represses MEF2-activated muscle gene expression.     |
|                                  | miR-23a         | Inhibits myogenic differentiation by silencing Myosin heavy chain 1, 2, and 4 expression.                                             |
|                                  | miR-27a/b       | Induces skeletal muscle hypertrophy by down regulating Myostatin, an inhibitor of myogenesis.                                         |
|                                  | miR-29          | Enhances muscle differentiation by repressing polycomb proteins. MiR-29 also inhibits proliferation by down regulating Akt3 in vitro. |
|                                  | miR-133         | Enhances myoblast proliferation by negatively regulating SRF.                                                                      |
|                                  | miR-206         | Promotes myoblast differentiation and regeneration by targeting Pax7.                                                              |
|                                  | miR-675-3p and  | Induce myogenesis and differentiation of satellite cells during regeneration.                                                       |
|                                  | miR-675-5p      |                                                                                                                                      |
| Exercise                         | miRNAs          | miRNAs in skeletal muscle and serum are differentially regulated depending on type of exercise, age of the subjects and the duration of exercise. However, myomiRs miR-1, miR-133, miR-208, and miR-486 are upregulated in most of the exercise regimens indicating their role in hypertrophy, regeneration, and maintenance of healthy skeletal muscle. |
| Atrophy                          | MyomiRs         | MyomiRs, miR-1-1, miR-1-2, miR-133a, miR-133b, and miR-206 are downregulated in TWEAK induced muscle wasting.                         |
|                                  | miR-1           | Upregulated in Dex induced muscle atrophy and targets HSP70 leading to upregulation of MuRF1 and Atrogin-1.                          |
|                                  | miR-23a         | Confers resistance to skeletal muscle atrophy by post-transcriptional regulation of Atrogin1 and MuRF1.                             |
|                                  | miR-29          | Reduced levels in muscle of mice with Chronic kidney diseases (CKD) lead to increased levels of YY1 protein inhibiting the satellite cell differentiation and muscle regeneration. |
|                                  | miR-146a        | Elevated expression during muscle wasting leads to downregulation of Numb and TRAF6 involved in satellite cell activation and AKT signaling respectively resulting in impaired regeneration. |
|                                  | miR-486         | Mimics for miR-486 rescued muscle atrophy in CKD mice by negatively regulating FoxO1 and PTEN.                                    |
| Aging                            | miR-29          | Upregulated during aging, inhibits muscle regeneration by targeting IGF-1 and p85α that decreases the overall protein translation during aging. |
|                                  | miR-181         | Decreased levels during aging lead to higher levels of targets like TNF-α, IL-6, IL-1β, and IL-8 in the muscle during aging.        |
|                                  | miR-206         | Increased levels in aging skeletal muscle could be conferring resistance to muscle atrophy.                                         |
| Duchenne muscular dystrophy      | miR-29          | Reduced levels of miR-29 result in decreased muscle regeneration and increased fibrogenesis in mdx muscle.                         |
|                                  | miR-31          | Higher levels of miR-31 augment pathology of dystrophic muscle.                                                                     |
|                                  | miR-145 and -133a | Increased serum levels are potential biomarkers in a mouse model of DMD.                                                             |
|                                  | miR-199a-5p     | Increased levels in dystrophic muscle affect myogenesis by targeting WNT signaling proteins necessary for cell proliferation and differentiation. |
|                                  | miR-206         | Elevated levels in serum are a potential biomarker for DMD.                                                                        |
|                                  | miR-486         | Reduced levels in mdx mice affect cell cycle and muscle regeneration by targeting PTEN/AKT pathway and platelet-derived growth factor receptor β. |

Functional significance of miRNAs in myogenesis, exercise, disease, and aging of skeletal muscle.

cell cycle. Additionally, miR-206 might indirectly down regulate DNA-Binding Protein Inhibitor (Id1-3) and Myogenic Repressor (MyoR), inhibitors of myogenic transcription factors like MyoD and regulate myoblast differentiation (Kim et al., 2006). The promyogenic activities of miR-206 and -486 were also evident in a study by Dey et al. (2011), in which they showed that miR-206 and -486 promoted myoblast differentiation by targeting Pax7, a paired box transcription factor that inhibits differentiation by negatively regulating MyoD levels. Moreover MyoD was shown to induce the expression of miR-206 and -486 (Dey et al., 2011). MiR-23a, a ubiquitous miRNA was shown to inhibit myogenic differentiation by targeting the 3' UTRs of fast Myosin heavy chain 1, 2, and 4 transcripts (Wang et al., 2012a,b). Many studies have suggested that miR-29 is a positive regulator of myogenesis. Huating et al. (2008) deciphered that NF-kB repressed miR-29 through Yin Yang 1 (YY1) protein, a part of Polycomb complex
during myoblast proliferation. During myogenesis, when NF-kB and subsequently YY1 levels were reduced, miR-29 expression was stimulated. MiR-29 was then able to enhance differentiation by inhibiting YY1 in the C2C12 myoblasts. Furthermore, miR-29 expression was downregulated in Rhabdomyosarcomas (RMS) through epigenetic silencing and its overexpression was able to rescue differentiation in RMS cell line (Huating et al., 2008). Another component of Polycomb repressive complex, RING1, and YY1 binding protein (Rybp) has the target sequence for miR-29 in its 3' UTR. Moreover, down-regulation of Rybp in C2C12 and regenerating skeletal muscle coincided with myogenesis indicating that Rybp inhibits C2C12 myoblast differentiation and muscle regeneration. The Rybp and YY1 complex was found to be present on many myogenic gene promoters including miR-29 suggesting the presence of Rybp-miR-29 feedback loop. Concomitant with increased expression of Rybp, an accumulation of Enhancer of zeste homolog 2 (Ezh2) and trimethylation of H3K27 at myogenic gene loci has been observed (Zhou et al., 2012). These findings clearly show that miR-29 mediates the repression of Polycomb complex consequently influencing the chromatin of myogenic genes during skeletal muscle differentiation. In a recent study, Wei et al. (2013) showed that miR-29 inhibited myoblast proliferation and induced differentiation through a more direct mechanism by down regulating Akt3 (a member of the serine/threonine protein kinase family responsive to growth factor cell signaling). Overexpression of Akt3 increased myoblast proliferation and reduced myoblast differentiation and resisted miR-29 mediated inhibition (Wei et al., 2013).

Skeletal muscle cell differentiation was also inhibited when miR-186 was overexpressed in myoblasts. MiR-186 was shown to directly target myogenin, which is a key regulator of skeletal muscle differentiation (Antoniou et al., 2014). Recently, an interesting mechanism involved in myoblast differentiation has been reported by de la Garza-Rodea et al. (2014) whereby S1P lyase (SPL) an enzyme that degrades sphingosine-1-phosphate (SIP) was shown to regulate myoblast differentiation by regulating the expression of miR-1, miR-206, and miR-486 (de la Garza-Rodea et al., 2014). Another novel discovery is of miR-675-3p and miR-675-5p, which are coded in the exon1 of long non-coding RNA H19, were shown to induce myogenesis and differentiation of satellite cells during regeneration. MiR-675-3p and miR-675-5p target the 3' UTRs of Smads and DNA replication initiation factor Cdk6 thus allowing the myoblasts to differentiate and regenerate the muscle (Dey et al., 2014).

One other miRNA that has been observed to play a role in myogenesis is miR-27a/b. MiR-27a/b negatively regulates Myostatin, an inhibitor of myogenesis (Huang et al., 2012; McFarlane et al., 2014). Antagonization of miR-27a/b led to higher Myostatin expression, decreased myoblast proliferation, and reduced satellite cell activation. While overexpression of miR-27a/b downregulated Myostatin and induced skeletal muscle hypertrophy (McFarlane et al., 2014).

Skeletal muscle is also known for its remarkable ability to undergo muscle regeneration by virtue of satellite cells. Satellite cells stay quiescent in resting muscle however once stimulated; enter cell cycle and differentiation program. Satellite cells are known to express quiescence marker genes such as Pax7. Consistently, miR-1 and miR-206 were shown to be upregulated in satellite cells after muscle injury and induced muscle regeneration by targeting Pax7 (Chen et al., 2010). Recently, miR-31 was shown to maintain satellite cells in quiescent state through the regulation of Myf5 mRNA in mRNP granules. Once the satellite cells were activated miR-31 was degraded in the mRNP granules, Myf5 mRNA became available for translation and Myf5 protein levels increased in the cells to initiate differentiation (Crist et al., 2012). This remarkable mechanism keeps the satellite cells in quiescent but “ready” state to enter cell cycle for muscle growth and regeneration.

**MiRNAs AND EXERCISE**

Skeletal muscle is a highly contractile tissue and physical activity is essential for maintaining muscle mass. It is apparent that exercise is a potent stimulus for satellite cell activation and muscle protein synthesis. Specifically, resistance exercise increases skeletal muscle mass by hypertrophy of muscle fibers (Mayhew et al., 2009; Stepto et al., 2009; Dreyer et al., 2010). Previous studies have indicated that exercise induces changes both at the genetic and epigenetic levels. Several miRNAs are differentially regulated during and after exercise, and some miRNAs are secreted in to circulation (Baggish et al., 2011; Davidsen et al., 2011).

The expression of myomiRs miR-1 and miR-133a was upregulated in young men soon after an acute exposure to endurance exercise (Nielsen et al., 2010). The increased expression of these myomiRs after acute endurance exercise correlates with upregulated levels of MyoD, myogenin, and MRF4, the myogenic transcription factors involved in myomiR expression (Kadi et al., 2004; Sweetman et al., 2008). It is noteworthy that within a fortnight of discontinuation of exercise, the myomiR levels were similar to the pre-exercise levels. However, the downstream targets and the signaling mechanisms affected by the myomiRs in this exercise regimen are yet to be confirmed. In an attempt to understand the basis of variable response of individuals to resistance exercise, differential expression of 21 abundant miRs was determined in the muscle of men subjected to resistance training for 12 weeks (Davidsen et al., 2011). After the training low responders did not gain any noticeable muscle mass and miR-378, miR-29a, and miR-26a levels were reduced while miR-451 was higher in the muscle of low responders (Davidsen et al., 2011). Interestingly, the expression of miR-378, miR-29a, and miR-26a was unaltered in the muscle of high responders which was alluded to be a compensatory effect. The results of this study show a correlation between the levels of miR-378 and muscle hypertrophy induced by exercise. Russell et al. (2013) reported that miR-1, miR-133a/b, and miR-181a were higher and miR-23a, miR-23b, and miR-31 were lower in the muscle of subjects after 3 h of an acute level of endurance cycling (Russell et al., 2013). The miRNA levels of Drosha, Dicer and Exportin involved in miRNA biogenesis were also up regulated.

It appears that exercise not only affects miRNA expression in the muscle tissue but also in circulation. After acute resistance exercise, miR-149* expression was more while miR-146a and miR-221 expression was lower in circulation of the subjects (Sawada et al., 2013). It might be that decrease in miR-146a and miR-221 allows the muscle regeneration to proceed since these
miRNAs affect differentiation (Cardinali et al., 2009; Kuang et al., 2009). Aoi et al. (2013) observed that circulatory levels of miR-486 were reduced after acute and chronic exercise in young men. MiR-486 is expressed at a higher level in muscle than other tissues and was shown to target Phosphatase and tensin homolog (PTEN), an inhibitor of PI3K/AKT pathway (Small et al., 2010). The PI3K/AKT pathway is downstream of Insulin signaling therefore miR-486 can regulate glucose uptake through PTEN in skeletal muscle. Based on these results, Aoi et al. (2013) proposed that miR-486 could be playing a role in exercise induced metabolic adaptations (Aoi et al., 2013). Alexander et al. (2013a,b) analyzed the expression profile of miRNAs and their regulatory targets in athletes who performed 30 min of exercise followed by a rest for 30 or 60 min. It is noteworthy that circulatory miR-181a-5p and clustered miRs miR-27a-5p and miR-24-2-5p were up regulated immediately after exercise followed by a decrease during the relaxation. The expression of some of the target genes of these miRNAs indicated that these miRNAs might be playing a role in adaptation during exercise (Alexander et al., 2013a).

MyomiRs miR-1, miR-133a and cardiac miR-208a were robustly upregulated in the circulation of subjects soon after aerobic exercise like marathon and regressed to normal levels 24 h after the marathon. On the other hand, the proteins involved in skeletal muscle injury, cardiac damage, and inflammation were upregulated after marathon and continued to be higher 24 h after marathon. These results suggest that circulatory miRNAs may be indicators of real-time changes induced by exercise and oxidative ability of muscles (Baggish et al., 2014; Mooren et al., 2014). Recently, Nielsen et al., 2014 compared the expression of miRNAs after acute and endurance exercise and discovered a pattern of miRNAs, which was unique to each type of exercise (Nielsen et al., 2014).

### MiRNAs IN MUSCLE ATROPHY

Muscle atrophy is characterized by loss of muscle mass. The loss of muscle mass is due to either enhanced degradation of muscle proteins and or reduced protein synthesis in skeletal muscle. Enhanced degradation of muscle sarcromic proteins, myosin heavy chains (MyHC) is mediated through E3 ubiquitin ligases Atrogin-1 and MuRF1 (Lecker et al., 2004; Sachock et al., 2007; Lokireddy et al., 2012; Sriram et al., 2014). Several muscle atrophy-inducing stimuli have been reported to stimulate these ubiquitin ligases. Recently, post-transcriptional regulation of Atrogin-1 and MuRF1 through miR-23a has been observed (Wada et al., 2011) indicating that miR-23a is a regulator of muscle atrophy. Indeed, overexpression of miR-23a in myotubes and skeletal muscle resulted in resistance to glucocorticoid Dexamethasone (Dex) induced muscle atrophy (Wada et al., 2011). MiR-23a was also found to be downregulated due to reduced calcineurin/NFAT signaling in the muscle of Dex treated mice (Hudson et al., 2014). Dex treatment was also found to enhance its exosomal packaging.

High doses of Dex or Myostatin induce severe skeletal muscle atrophy. In our recent publication we described the role of miR-1 in Dex-mediated atrophy (Kukreti et al., 2013). In this study we have shown a novel miR-1-mediated mechanism through which Dex promotes skeletal muscle atrophy by targeting the protective protein HSP70. We showed glucocorticoid receptor mediated miR-1 upregulation after both Dex and Myostatin treatment in C2C12 myotubes and animal models of Dex-induced muscle atrophy. Inhibition of miR-1 in C2C12 myotubes attenuated the Dex-induced increase in atrophy related proteins confirming a role for miR-1 in atrophy. Increased miR-1 during atrophy repressed HSP70 expression, which resulted in decreased phosphorylation of AKT, due to loss of HSP70 bound pAKT. The loss of pAKT lead to decreased phosphorylation, and thus, enhanced activation of Forkhead box O3 (FoxO3) and upregulation of MuRF1 and Atrogin-1. Thus, we proposed a model whereby Dex and Myostatin mediated atrophic signals were integrated through miR-1, which then directly or indirectly, inhibited the proteins involved in resisting atrophy.

Chronic kidney diseases (CKD) are associated with muscle wasting. Besides the mechanisms of protein degradation and reduced protein synthesis, reduced muscle satellite cell (stem cell) function also plays a role in muscle atrophy. Several genetic and epigenetic processes that affect satellite cell function have been recognized previously. Not so long ago, Wang et al. (2012a,b) demonstrated that satellite cell function is impaired in the muscles of CKD mice. The differentiation of these satellite cells was impaired due to an increase in YY1 protein, a well-established inhibitor of myogenesis. YY1 protein was found to be upregulated in the satellite cells of CKD muscle. Microarray analysis of the muscle from mice with CKD revealed that miR-29 expression was downregulated in the satellite cells. One of the targets of miR-29 is YY1; hence reduction in miR-29 expression released the repression on YY1 and caused poor muscle differentiation and regeneration. Overexpression of miR-29 in the C2C12 cells enhanced the differentiation and rescued the repression in YY1 overexpressing cells indicating miR-29-mediated regulation of YY1 and myoblast differentiation.

To circumvent the CKD induced atrophy, Jing et al. (2012) used miR-486 mimic and transfected in the muscle of mice with CKD. They observed that miR-486 mimic was able to rescue the atrophy phenotype despite CKD. Two important targets of miR-486 are Forkhead box O1 (FoxO1) and PTEN. PTEN is known to dephosphorylate AKT and dephosphorylation of AKT leads to dephosphorylation of FoxO1 and thus its nuclear translocation. Furthermore, miR-486 inhibits FoxO1 at the protein level. These two mechanisms combined together effectively render the FoxO1 mediated atrophy signaling inactive in miR-486 mimic treated CKD affected muscle and Dex treated myotubes (Jing et al., 2012).

Several cytokines play a role in inducing atrophy in skeletal muscle. Newly found cytokine TNF-like weak inducer of apoptosis (TWEAK) belongs to TNF family and has been shown to cause muscle wasting (Panguluri et al., 2010). One of the mechanisms proposed for induction of muscle wasting by TWEAK is via regulation of differential expression of several miRNAs in myotubes. Myomirs including miR-1-1, miR-1-2, miR-133a, miR-133b, and miR-206 were downregulated while miR-146a and miR-455 were upregulated upon treatment of myotubes with TWEAK protein. Panguluri et al. (2010) suggested that reduced levels of Myomirs would affect myogenesis during muscle wasting and increased levels of miR-146a would target genes like Numb and TRAF6. Numb is involved in satellite cell activation and...
downregulation of numb by miR-146a would negatively affect muscle regeneration. TRAF6 has been shown to activate AKT signaling that is known to enhance protein synthesis and thus hypertrophy signaling.

Muscle atrophy is also associated with fiber type changes consistent with slow to fast fiber type switching (Baldwin and Haddad, 2002). The fiber type change is manifested through the downregulation of slow twitch beta-myosin heavy chain (β-MyHC) and an increase in fast twitch MyHC (Type IIB and IIX) (Stevenson et al., 2003). Earlier, transcription factors, Pura, Pur β, and SP3, which regulate β-MyHC expression during atrophy, were identified. Recently miR circuitry regulating β-MyHC at the post-transcriptional level has been discovered. Introns of Myh6 (α-MHC), Myh7, and Myh7b encode miR-208a, -208b, and -499 respectively and these miRs have been shown to regulate MyHC levels. Mir-208a has been shown to target a thyroid hormone receptor cofactor (Thrap1), which is known to repress β-MyHC levels indicating that miR-208a activates β-MyHC gene expression indirectly (Van Rooij et al., 2008). The same group has also reported that miR-499 was instrumental in inducing fast-to-slow muscle fiber switching phenotype by reducing the expression of Sox6 transcription factor. Sox6, a repressor of β-MyHC gene expression increased during atrophy. Additionally, miR-208a and b can regulate the expression of miR-499 through its host gene β-MyHC gene expression by repressing the transcription factor, e.g., Sox6. These miRNAs are an excellent example of circuitry (McCarthy et al., 2009).

In another study, levels of miR-696 were up regulated in the muscles of mice subjected to hind limb immobilization while levels of PGC-1 alpha, a target of miR-696 were decreased. Consistent with this observation miR-696 over expressing myocytes showed a decrease in PGC-1alpha, which is involved in mitochondrial function and metabolism (Liang and Ward, 2006). Furthermore, the expression of miR-696 was reduced in the muscles of mice after exercise and the levels of PGC-1 alpha were increased. These results indicate the importance of miR-696 in skeletal muscle atrophy, metabolism and adaptations (Aoi et al., 2010).

**MiRNAs IN SKELETAL MUSCLE AGING**

Naturally occurring muscle wasting during aging is known as sarcopenia. Sarcopenia starts from the age of forty years in humans and gets worse with each decade. Even though it is known to exist, the mechanisms behind sarcopenia are not fully known. With increasing understanding of miRs, it is apparent that miRs also play a role during aging.

Drummond et al. (2008) analyzed the expression of myomirs, miR-1, miR-133, and miR-206 in the skeletal muscle of old and young humans subjected to exercise and administration of leucine rich amino acid solution. The results indicated that basal expression of pri-miRNA-1-1, -1-2, -133a-1, and -133a-2 was higher in older compared with young men. Furthermore, these primary miRNAs were downregulated at 6h after exercise only in the young men. Finally, it was inferred that an increased primary miRNA expression occurs during aging; the effect of anabolic stimulus on miRNA levels was perturbed in older men. Interestingly, the expression of primary miR-206 continued to be higher in older men even after anabolic stimulus however the expression of mature miR-206 did not alter (Drummond et al., 2008).

Subsequently, Hamrick et al. (2010) carried out a microarray analysis in the muscles of 12 and 24 month old mice and observed that miR-206, -698, and -468 increased during aging and miR-434, -455, -382, -181a, and -221 were reduced (Hamrick et al., 2010). Clop et al have demonstrated the role of miR-206 in skeletal muscle hypertrophy previously (Clop et al., 2006), therefore the assumption for the action of miR-206 during aging is to protect muscle from atrophy. The targets for miR-698 and -468 have not been validated in skeletal muscle yet; Hamrick et al. predicted that cardiotrophin1 could be the target for miR-698 in skeletal muscle since cardiotrophin1 was found to inhibit myogenic regulatory factors during differentiation (Miyake et al., 2009). In line with the protective roles of some of the miRs in skeletal muscle during aging, miR-221 also fits in that role. Higher levels of miR-221 inhibit differentiation of myoblasts and during normal course of myoblast differentiation its expression is reduced. Taken together, these miRNAs are helping skeletal muscle to maintain the differentiation phenotype during aging. Mir-455 has been shown to be involved in brown adipocyte differentiation (Walden et al., 2009) and how its downregulation in aging skeletal muscle would affect the muscle function is a matter of speculation.

A recent RNA sequencing study by Mercken et al. (2013) revealed differential expression of miRs in the skeletal muscles of old and young rhesus monkeys. They observed an increase in the expression of several novel miRNAs including miR-744-5p in the old skeletal muscle. The expression of myomir, miR-181a was downregulated and calorie restriction was able to revert the levels of miR-181a in the old muscle. Based on the earlier reports showing Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), Interleukin-1beta (IL-1β), and Interleukin-8 (IL-8) as the targets of miR-181a Hutchison et al. (2013); Xie et al. (2013) and Mercken et al. (2013) proposed that decrease in miR-181a could be responsible for an increase in the mentioned inflammatory cytokines in the muscle during aging.

Similarly, microarray analysis of miRNAs in muscles from young (4 months) and old (28 months) rats was shown to alter (Hu et al., 2014a,b). Several miRNAs were up or down regulated. MiR-29 has been seen to be consistently upregulated during sarcopenia, senescence, or aging. In the aged rat muscle, miR-29 was shown to target Insulin like Growth Factor-1 (IGF-1), Phosphatidilinositide 3-kinase p85 alpha regulatory subunit (p85α) and Myeloblastosis-related protein B (B-myb) transcripts. By targeting IGF-1 and p85α, miR-29 inhibited muscle protein synthesis and myogenesis since IGF-1 and p85α are well established signaling molecules for protein translation and a decrease in these proteins was observed during muscle atrophy including sarcopenia (Owino et al., 2001; Barbour et al., 2005; Park et al., 2009; Smith et al., 2012). Overexpression of miR-29 in skeletal muscle also resulted in an increase in cell cycle arrest proteins, Cyclin-Dependent kinase inhibitor 2A, (p16ink4A) and Retinoblastoma protein (pRB) in agreement with the increased expression of these proteins in aged muscle (Hu et al., 2014a,b). Thus, miR-29 regulates the levels of various proteins directly or indirectly eventually resulting in muscle atrophy during aging.
MiRNAs in Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is caused by mutations in dystrophin gene leading to progressive muscle wasting. In DMD pathology muscle tissue undergoes severe cellular and molecular changes. Several studies have determined the expression of myomiRs, miR-1, -133, and -206 levels in serum of DMD patients and found that these myomiRs were upregulated. Consistently, miR-206 correlates with DMD pathology and thus could be a useful biomarker for DMD along with creatine kinase (Cacciarelli et al., 2011; Mizuno et al., 2011; Vignier et al., 2013; Zaharieva et al., 2013; Hu et al., 2014a; Roberts et al., 2014). Furthermore, miR-145 and miR-133a were shown to be potential biomarkers in a mouse model of DMD (Endo et al., 2013).

Microarray analyses of miRNAs have been conducted in the muscles from DMD patients and dystrophic animal models. There have been some inconsistencies in the results due to the type of muscle used and animal model itself. Intriguingly, the miRNAs expressed in diaphragm of X chromosome-linked muscular dystrophy (mdx) mice were not significantly different from the wild type diaphragm (Greco et al., 2009; Thomas et al., 2012). MyomiR-486 expression was reduced in mdx muscle. MiR-486 was shown to regulate PTEN/PAK pathway and platelet-derived growth factor receptor β thus affecting the cell cycle and muscle regeneration in mdx muscle (Alexander et al., 2011). Mdx mice also showed reduced levels of miR-29 (Eisenberg et al., 2007; Greco et al., 2009). MiR-29 has been shown to positively regulate myogenesis and reduce fibrogenesis (Lijun et al., 2012). Indeed, overexpression of miR-29 in mdx muscle increased regeneration concomitant with decreased fibrosis (Lijun et al., 2012). Increased expression of miR-31 was reported in DMD patients and mdx mice (Greco et al., 2009; Thomas et al., 2012; Roberts et al., 2014). MiR-31 has been shown to regulate the dystrophin levels by targeting the 3’ UTR of dystrophin. Hence, Cacciarelli et al. (2011) have proposed that inhibition of miR-31 would improve dystrophin expression during treatment of dystrophy through exon skipping. MiR-199a-5p levels were increased in human dystrophic skeletal muscle. MiR-199a-5p regulates the proteins of WNT signaling pathway namely Frizzled 4 (FZD4), Jagged1 (JAG1), and WNT2. These proteins play a role in cell proliferation and differentiation thus downregulation of these proteins by miR-199a-5p would affect myogenesis in dystrophic muscle (Alexander et al., 2013b).

Perspective

It is evident that miRNAs are a critical component of regulatory mechanisms in muscle (Table 1). MiRNAs also appear to be versatile in their function for example miR-1 has a role in myogenesis as well as muscle atrophy. These findings also suggest that miRNAs could have context specific function. It is fascinating to note that miRNAs are not simply regulating their targets post-transcriptionally but also in many instances their own transcription via various circuitries. Many miRNAs are involved in disease conditions therefore strategies for usage of miRNAs or antagonists could be developed for therapeutic purposes. Indeed, mimics for miR-34a are being tried in a Phase I trial by Mirna Therapeutics to increase expression of miR-34a in tumors and Miravirsen (Santaris Pharma), a LNA-modified oligonucleotide inhibitor of miR-122 has been tried in humans for the treatment of Hepatitis-C (Hyderabad and Badalan-Very, 2013). As per these results, utility of miRNA-based therapeutics appears to be encouraging. Furthermore, the fact that expression of miRNAs can be regulated by external cues such as exercise, incorporation of such external cues in therapeutic approaches needs to be considered.

Acknowledgment

We acknowledge the support of National Research Foundation, Singapore.

References

Alexander, G. T., Diana, V. M., Ashgar, A., Timur, R. S., Dmitry, A. S., Maxim, U. S., et al. (2013a). Dynamically regulated miRNA-mRNA networks revealed by exercise. BMC Physiol. 13:9. doi: 10.1186/1472-6793-13-9
Alexander, M. S., Casar, J. C., Motohashi, N., Myers, J. A., Eisenberg, L., Gonzalez, R. T., et al. (2011). Regulation of DMD pathology by an ankyrin-encoded miRNA. Skelet. Muscle 1:27. doi: 10.1080/2044-5040.1-27
Alexander, M. S., Kawahara, G., Motohashi, N., Casar, J. C., Eisenberg, L., Myers, J. A., et al. (2013b). MicroRNA-199a is induced in dystrophic muscle and affects WNT signaling, cell proliferation, and myogenic differentiation. Cell Death Differ. 20, 1194–1208. doi: 10.1038/cdd.2013.62
Ambros, V. (2004). The functions of animal microRNAs. Nature 431, 350–355. doi: 10.1038/nature02871
Antoniou, A., Mastroyiannopoulos, N. P., Uney, J. B., and Phylactou, L. A. (2014). miR-186 inhibits muscle cell differentiation through myogenin regulation. J. Biol. Chem. 289, 3923–3935. doi: 10.1074/jbc.M113.507343
Aoi, W., Ichikawa, H., Mune, K., Tanimura, Y., Mizushima, K., Naito, Y., et al. (2013). Muscle-enriched microRNA miR-486 decreases in circulation in response to exercise in young men. Front. Physiol. 4:60. doi: 10.3389/physiol.2013.00080
Aoi, W., Naito, Y., Mizushima, K., Takanami, Y., Kawai, Y., Ichikawa, H., et al. (2010). The microRNA miR-696 regulates PGCl-α in mouse skeletal muscle in response to physical activity. Am. J. Physiol. Endocrinol. Metab. 298, E799–E806. doi: 10.1152/ajpendo.00448.2009
Baggish, A. L., Hale, A., Weiner, R. B., Lewis, G. D., Systrom, D., Wang, F., et al. (2011). Dynamic regulation of circulating microRNA during acute exhaustive exercise and sustained aerobic exercise training. J. Physiol. 589, 3983–3994. doi: 10.1113/jphysiol.2011.213363
Baggish, A. L., Park, J., Min, P. K., Isaacs, S., Parker, B. A., Thompson, P. D., et al. (2014). Rapid upregulation and clearance of distinct circulating microRNAs after prolonged aerobic exercise. J. Appl. Physiol. 116, 522–531. doi: 10.1152/japplphysiol.01141.2013
Baldwin, K. M., and Haddad, F. (2002). Skeletal muscle plasticity: cellular and molecular responses to altered physical activity paradigms. Am. J. Physiol. Med. Rehabil. 81, S40–S51. doi: 10.1097/00002060-200211001-00006
Barbour, L. A., Mizanoor Rahman, S., Gurevich, I., Leitner, J. W., Fischer, S. J., Roper, M. D., et al. (2005). Increased P85α is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J. Biol. Chem. 280, 37489–37494. doi: 10.1074/jbc.M50696200
Bartel, D. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233. doi: 10.1016/j.cell.2009.01.002
Brennecke, J., Stark, A., Russell, R. B., and Cohen, S. M. (2005). Principles of microRNA-target recognition. PLoS Biol. 3:e85. doi: 10.1371/journal.pbio.0030085
Brodersen, P., and Voinnet, O. (2009). Revisiting the principles of microRNA target recognition and mode of action. Nat. Rev. Mol. Cell Biol. 10, 141–148. doi: 10.1038/nrm2619
Bushati, N., and Cohen, S. M. (2007). microRNA functions. Annu. Rev. Cell Dev. Biol. 23, 175–205. doi: 10.1146/annurev.cellbio.23.090506.123406
Cacciarelli, D., Legnini, I., Martone, J., Cazzella, V., Amico, A., Bertini, E., et al. (2011). miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol. Med. 3, 258–265. doi: 10.1002/emmm.201100133
Lee, Y., Hur, I., Park, S. Y., Kim, Y. K., Suh, M. R., and Kim, V. N. (2006). The role of PACT in the RNA silencing pathway. EMBO J. 25, 522–532. doi: 10.1038/sj.emboj.7600942
Leung, A. K., and Sharp, P. A. (2010). MicroRNA functions in stress responses. Mol. Cell. 40, 205–215. doi:10.1016/j.molcel.2010.09.027
Lewis, B. P., Burge, C. B., and Bartel, D. P. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15–20. doi:10.1016/j.cell.2004.12.035
Liang, H., and Ward, W. F. (2006). PGC-1α: a key regulator of energy metabolism. Adv. Physiol. Educ. 30, 145–151. doi:10.1152/advan.00052.2006
Lijun, W., Liang, Z., Peijong, J., Leina, L., Xiaona, C., Huiyao, L., et al. (2012). Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis. Mol. Ther. 20, 1222–1233. doi:10.1038/mi.2012.35
Lokireddy, S., Wijesoma, I. W., Bonala, S., Wei, M., See, S. K., McFarlane, C., et al. (2012). Myostatin is a novel tumoral factor that induces cancer cachexia. Biochem. J. 446, 23–36. doi:10.1042/BJ20110204
Mayhew, D. L., Kim, J.-S., Cross, J. M., Ferrando, A. A., and Bamman, M. M. (2009). Translational signaling responses preceding resistance training-mediated myofiber hypertrophy in young and old humans. J. Appl. Physiol. 107, 1655–1662. doi:10.1152/japplphysiol.91234.2008
McCarthy, J. I., and Esser, K. A. (2007). MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J. Appl. Physiol. 102, 306–313. doi:10.1152/japplphysiol.00932.2006
McCarthy, J. I., Esser, K. A., Peterson, C. A., and Dupont-Versteegden, E. E. (2009). Evidence of myomir network regulation of β-myosin heavy chain gene expression during skeletal muscle atrophy. Physiol. Genomics 39, 219–226. doi:10.1016/j.physiogenomics.0004.2009
McFarlane, C., Vajjala, A., Arigela, H., Lokireddy, S., Ge, X., Bonala, S., et al. (2014). Negative auto-regulation of myostatin expression is mediated by smad3 and microRNA-27. PLoS ONE 9:e87687. doi:10.1371/journal.pone.0087687
Meister, G., and Tuschl, T. (2004). Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343–349. doi:10.1038/nature02873
Mercken, E. M., Majounie, E., Ding, J., Guo, R., Kim, J., Bernier, M., et al. (2013). Age-associated miRNA alterations in skeletal muscle from rhesus monkeys reveals potential mechanisms of TWEAK-induced skeletal muscle wasting in aged monkeys. FEBS Lett. 591, 4637–4653. doi:10.1111/febs.2013.253695
Sackeck, J. M., Hyatt, J.-P. K., Raffaello, A., Jagoe, R. T., Roy, R. R., Edgerton, V. R., et al. (2007). Rapid diuresis and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. PASEB J. 21, 140–155. doi:10.1096/fj.05-6604com
Sawada, S., Kom, M., Wada, S., Ushida, T., Suzuki, K., and Akimoto, T. (2013). Profiling of circulating MicroRNAs after a bout of acute resistance exercise in humans. PLoS ONE 8:e70823. doi:10.1371/journal.pone.0070823
Small, E. M., O’Rourke, J. R., Moresi, V., Sutherland, L. B., Macnally, J., Gerard, R. D., et al. (2010). Regulation of PI3-kinase/akt signaling by muscle-enriched microRNA-486. Proc. Natl. Acad. Sci. U.S.A. 107, 4218–4223. doi:10.1073/pnas.100300107
Smith, S. S., Kessler, C. B., Shenoy, V., Rosen, C. J., and Delany, A. M. (2012). IGF-I 3′ untranslated region: strain-specific polymorphisms and motifs regulating IGF-I in osteoblasts. Endocrinology 154, 253–262. doi:10.1210/en.2012-1476
Sriram, S., Subramanian, S., Juvvuna, P. K., Ge, X., Lokiredy, S., McFarlane, C. D., et al. (2014). Myostatin augments muscle-specific ring finger protein-1 expression through an NF-κB independent mechanism in SMADM3 null muscle. Mol. Endocrinol. 28, 317–330. doi:10.1210/me.2013-1179
Stepto, N. K., Coffey, V. G., Carey, A. L., Ponnampalam, A. P., Canny, B. J., Powell, D., et al. (2009). Global gene expression in skeletal muscle from well-trained strength and endurance athletes. Med. Sci. Sports Exerc. 41, 546–565. doi:10.1249/MSS.0b013e31818c6be9
Stevenson, E. J., Giresi, P. G., Koncarev, A., and Kandarian, S. C. (2003). Global analysis of gene expression patterns during disuse atrophy in rat skeletal muscle. J. Physiol. 551, 33–48. doi:10.1113/jphysiol.2003.044701
Sweetman, D., Goljanek, K., Rathjen, T., Oustanina, S., Braun, T., Dalmay, T., et al. (2008). Specific requirements of MRFs for the expression of muscle specific microRNAs, miR-1, miR-206 and miR-133. Dev. Biol. 321, 491–499. doi:10.1016/j.ydbio.2008.06.019
Thomas, C. R., Blomberg, K. E. M., Graham, M., Samir, E. L. A., Caroline, G., Corinne, B., et al. (2012). Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy. Mol. Ther. Nucleic Acids 1:e39. doi:10.1038/mtna.2012.26
Van Rooij, E., Liu, N., and Olson, E. N. (2008). MicroRNAs flex their muscles. Trends Genet. 24, 159–166. doi:10.1016/j.tig.2008.01.007
Vignier, N., Amor, F., Fogel, P., Duvallet, A., Poupjot, J., Charrier, S., et al. (2013). Distinctive serum miRNA profile in mouse models of striated muscular pathologies. PLoS ONE 8:e55281. doi:10.1371/journal.pone.0055281
Wada, S., Kato, Y., Okutsu, M., Miyaki, S., Suzuki, K., Yan, Z., et al. (2011). Translational suppression of atrophic regulators by MicroRNA-23a integrates resistance to skeletal muscle atrophy. J. Biol. Chem. 286, 38456–38465. doi:10.1074/jbc.M111.271270
Walden, T. B., Timmons, J. A., Keller, P., Nedergaard, J., and Cannon, B. (2009). Distinct expression of muscle-specific MicroRNAs (myomirs) in brown adipocytes. J. Cell. Physiol. 218, 444–449. doi:10.1002/jcp.21621
Wang, L., Chen, X., Zheng, Y., Li, F., Lu, Z., Chen, C., et al. (2012a). MiR-23a inhibits myogenic differentiation through down regulation of fast myosin heavy chain isoforms. Exp. Cell Res. 318, 2324–2334. doi:10.1016/j.yexcr.2012.06.018
Wang, L., Zhou, L., Jiang, P., Lu, L., Chen, X., Lan, H., et al. (2012b). Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis. Mol. Ther. 20, 1222–1233. doi:10.1038/mt.2012.35
Wei, W., He, H. B., Zhang, W. Y., Zhang, H. X., Bai, J. B., Liu, H. Z., et al. (2013). miR-29 targets Akt3 to reduce proliferation and facilitate differentiation of myoblasts in skeletal muscle development. Cell Death Dis. 4:e668. doi:10.1038/cddis.2013.184
Xie, W., Li, Z., Li, M., Xu, N., and Zhang, Y. (2013). miR-181a and inflammation: miRNA homeostasis response to inflammatory stimuli in vivo. Biochem. Biophys. Res. Commun. 430, 647–652. doi: 10.1016/j.bbrc.2012.11.097

Zaharieva, I. T., Calissano, M., Scoto, M., Preston, M., Čirak, S., Feng, L., et al. (2013). Dystromirs as serum biomarkers for monitoring the disease severity in duchenne muscular dystrophy. PLoS ONE 8:e80263. doi: 10.1371/journal.pone.0080263

Zhao, Y., Samal, E., and Srivastava, D. (2005). Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436, 214–220. doi: 10.1038/nature03817

Zhao, Y., and Srivastava, D. (2007). A developmental view of microRNA function. Trends Biochem. Sci. 32, 189–197. doi: 10.1016/j.tibs.2007.02.006

Zhou, L., Wang, L., Lu, L., Jiang, P., Sun, H., and Wang, H. (2012). A novel target of MicroRNA-29, Ring1 and YY1-binding Protein (Rybp), negatively regulates skeletal myogenesis. J. Biol. Chem. 287, 25255–25265. doi: 10.1074/jbc.M112.357053

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 08 May 2014; accepted: 10 June 2014; published online: 26 June 2014.

Citation: Sharma M, Juvvuna PK, Kukreti H and McFarlane C (2014) Mega roles of microRNAs in regulation of skeletal muscle health and disease. Front. Physiol. 5:239. doi: 10.3389/fphys.2014.00239

This article was submitted to Striated Muscle Physiology, a section of the journal Frontiers in Physiology.

Copyright © 2014 Sharma, Juvvuna, Kukreti and McFarlane. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.